Chargement en cours...
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 o...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935287/ https://ncbi.nlm.nih.gov/pubmed/31920387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212559 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|